Galera Therapeutics (GRTX) Competitors $0.03 +0.00 (+13.08%) As of 07/3/2025 11:58 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. CLDI, BMRA, OBSV, CHRO, CVM, SLXN, PMCB, CYCC, INDP, and TCRTShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Calidi Biotherapeutics (CLDI), Biomerica (BMRA), ObsEva (OBSV), Chromocell Therapeutics (CHRO), CEL-SCI (CVM), Silexion Therapeutics (SLXN), Nuvilex (PMCB), Cyclacel Pharmaceuticals (CYCC), Indaptus Therapeutics (INDP), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Calidi Biotherapeutics Biomerica ObsEva Chromocell Therapeutics CEL-SCI Silexion Therapeutics Nuvilex Cyclacel Pharmaceuticals Indaptus Therapeutics Alaunos Therapeutics Galera Therapeutics (NASDAQ:GRTX) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Does the media prefer GRTX or CLDI? In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Calidi Biotherapeutics'average media sentiment score. Company Overall Sentiment Galera Therapeutics Neutral Calidi Biotherapeutics Neutral Do insiders & institutionals believe in GRTX or CLDI? 50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GRTX or CLDI more profitable? Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Calidi Biotherapeutics N/A N/A -344.45% Which has better valuation & earnings, GRTX or CLDI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.35-0.08Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Which has more risk & volatility, GRTX or CLDI? Galera Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. SummaryGalera Therapeutics beats Calidi Biotherapeutics on 4 of the 5 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.22M$790.73M$5.54B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio-0.081.3527.4320.23Price / SalesN/A226.97420.98118.64Price / CashN/A23.4436.8958.07Price / Book-0.016.298.045.67Net Income-$59.08M-$27.73M$3.18B$249.13M7 Day PerformanceN/A1.82%2.88%3.28%1 Month PerformanceN/A9.90%3.69%5.56%1 Year PerformanceN/A10.79%36.15%21.12% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera Therapeutics0.2939 of 5 stars$0.03+13.1%N/A-78.7%$2.22MN/A-0.0830Gap DownCLDICalidi Biotherapeutics0.2195 of 5 stars$0.26-9.8%$10.00+3,791.1%N/A$8.17M$50K0.0038BMRABiomerica0.5022 of 5 stars$3.14+3.5%N/A-7.9%$7.99M$5.41M-1.3560News CoverageNegative NewsOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150CHROChromocell TherapeuticsN/A$1.20+2.5%N/A-89.3%$7.91MN/A-0.974Gap UpCVMCEL-SCI0.3087 of 5 stars$2.43-1.2%N/A-92.5%$7.37MN/A-5.0643SLXNSilexion TherapeuticsN/A$0.83+1.3%$5.00+504.6%N/A$7.28MN/A0.00N/APMCBNuvilex0.9381 of 5 stars$1.06flatN/A-45.2%$7.27MN/A1.434CYCCCyclacel Pharmaceuticals0.6099 of 5 stars$0.32-1.9%N/A-99.9%$7.21M$40K-0.0114News CoverageStock SplitINDPIndaptus Therapeutics2.9402 of 5 stars$0.45-10.4%$8.50+1,797.3%-82.5%$7.18MN/A-0.306TCRTAlaunos Therapeutics0.3846 of 5 stars$4.34-3.1%N/A-22.8%$7.12M$10K0.0040 Related Companies and Tools Related Companies CLDI Competitors BMRA Competitors OBSV Competitors CHRO Competitors CVM Competitors SLXN Competitors PMCB Competitors CYCC Competitors INDP Competitors TCRT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts